Clinical Trial Update: Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence [Phase 2, Phase 3]

View source ↗

Summary

A single-arm Phase 2/3 clinical trial in hepatocellular carcinoma evaluating adjuvant therapy with Icaritin in combination with transarterial chemoembolization …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Icaritin (icaritin)

Snippet

Sponsor: Zhujiang Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2, Phase 3 | Status: RECRUITING